logo-loader
viewQ BioMed Inc.

Full interview: Q BioMed selects 'the perfect partner' to distribute its non-opioid bone pain relief drug Strontium-89

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the company has entered into an exclusive distribution agreement for its non-opioid, FDA-approved drug Strontium-89, which is aimed to control bone pain caused by cancer.

Corin says the company has chosen 'the perfect partner' in Jubilant Radiopharma, to distribute the drug to the US market, which he says is a leading pharmaceutical company specializing in nuclear medicine.

Quick facts: Q BioMed Inc.

Price: 1.65 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $38.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed advancing its liver cancer treatment through the pipeline

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the biotech will advance Uttroside-B in its portfolio and move it quickly towards monetization. Corin says the efficacy of Uttroside-B, a potent saponin, was demonstrated in a preclinical study published in the November 2016 issue of...

2 weeks, 1 day ago

2 min read